Role of TAZ as mediator of Wnt signaling.

PubWeight™: 3.05‹?› | Rank: Top 1%

🔗 View Article (PMID 23245942)

Published in Cell on December 13, 2012

Authors

Luca Azzolin1, Francesca Zanconato, Silvia Bresolin, Mattia Forcato, Giuseppe Basso, Silvio Bicciato, Michelangelo Cordenonsi, Stefano Piccolo

Author Affiliations

1: Department of Biomedical Sciences, University of Padua School of Medicine, viale Colombo 3, 35126 Padua, Italy.

Articles citing this

The Hippo pathway: regulators and regulations. Genes Dev (2013) 4.55

Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. Cell (2015) 2.31

Tumor-selective proteotoxicity of verteporfin inhibits colon cancer progression independently of YAP1. Sci Signal (2015) 1.52

TIAM1 Antagonizes TAZ/YAP Both in the Destruction Complex in the Cytoplasm and in the Nucleus to Inhibit Invasion of Intestinal Epithelial Cells. Cancer Cell (2017) 1.41

Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth. Nat Cell Biol (2015) 1.39

Wnt some lose some: transcriptional governance of stem cells by Wnt/β-catenin signaling. Genes Dev (2014) 1.33

Disease implications of the Hippo/YAP pathway. Trends Mol Med (2015) 1.32

YAP and TAZ: a nexus for Hippo signaling and beyond. Trends Cell Biol (2015) 1.29

The Hippo transducer TAZ interacts with the SWI/SNF complex to regulate breast epithelial lineage commitment. Cell Rep (2014) 1.24

Cell Competition Drives the Growth of Intestinal Adenomas in Drosophila. Curr Biol (2016) 1.24

Alternative Wnt Signaling Activates YAP/TAZ. Cell (2015) 1.21

The transcriptional regulators TAZ and YAP direct transforming growth factor β-induced tumorigenic phenotypes in breast cancer cells. J Biol Chem (2014) 1.17

Signal integration in TGF-β, WNT, and Hippo pathways. F1000Prime Rep (2013) 1.15

Aerobic glycolysis tunes YAP/TAZ transcriptional activity. EMBO J (2015) 1.11

Defined three-dimensional microenvironments boost induction of pluripotency. Nat Mater (2016) 1.11

Regulation of Wnt/β-catenin signaling within and from osteocytes. Bone (2013) 1.08

Signaling in Fibrosis: TGF-β, WNT, and YAP/TAZ Converge. Front Med (Lausanne) (2015) 1.07

Regulation of the Hippo pathway and implications for anticancer drug development. Trends Pharmacol Sci (2013) 1.07

SOX2 regulates YAP1 to maintain stemness and determine cell fate in the osteo-adipo lineage. Cell Rep (2013) 1.07

Genomic insights into WNT/β-catenin signaling. Trends Pharmacol Sci (2013) 1.00

β-Catenin destruction complex-independent regulation of Hippo-YAP signaling by APC in intestinal tumorigenesis. Genes Dev (2015) 0.96

A combination of Wnt and growth factor signaling induces Arl4c expression to form epithelial tubular structures. EMBO J (2014) 0.93

Transgenic expression of oncogenic BRAF induces loss of stem cells in the mouse intestine, which is antagonized by β-catenin activity. Oncogene (2014) 0.93

α-Catenin interacts with APC to regulate β-catenin proteolysis and transcriptional repression of Wnt target genes. Genes Dev (2013) 0.93

Transcriptional regulation of effector and memory CD8+ T cell fates. Curr Opin Immunol (2013) 0.91

The hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells. Mol Cell Biol (2015) 0.91

Noncanonical Wnt5a enhances Wnt/β-catenin signaling during osteoblastogenesis. Sci Rep (2014) 0.91

Integration of mechanical and chemical signals by YAP and TAZ transcription coactivators. Cell Biosci (2013) 0.91

The hippo pathway in heart development, regeneration, and diseases. Circ Res (2015) 0.91

The role of the hippo pathway in melanocytes and melanoma. Front Oncol (2013) 0.90

Nuclear signaling from cadherin adhesion complexes. Curr Top Dev Biol (2015) 0.90

What do mechanotransduction, Hippo, Wnt, and TGFβ have in common? YAP and TAZ as key orchestrating molecules in ocular health and disease. Exp Eye Res (2013) 0.90

Up-regulation of the Hippo pathway effector TAZ renders lung adenocarcinoma cells harboring EGFR-T790M mutation resistant to gefitinib. Cell Biosci (2015) 0.89

A Review: Molecular Aberrations within Hippo Signaling in Bone and Soft-Tissue Sarcomas. Front Oncol (2015) 0.88

Control of Proliferation and Cancer Growth by the Hippo Signaling Pathway. Mol Cancer Res (2015) 0.87

Canonical Wnt signalling activates TAZ through PP1A during osteogenic differentiation. Cell Death Differ (2014) 0.87

Amotl2a interacts with the Hippo effector Yap1 and the Wnt/β-catenin effector Lef1 to control tissue size in zebrafish. Elife (2015) 0.86

Transforming Growth Factor β Drives Hemogenic Endothelium Programming and the Transition to Hematopoietic Stem Cells. Dev Cell (2016) 0.84

Blending hippo and WNT: sharing messengers and regulation. Cell (2012) 0.84

On human pluripotent stem cell control: The rise of 3D bioengineering and mechanobiology. Biomaterials (2015) 0.84

Activation of Wnt/β-catenin signaling in a subpopulation of murine prostate luminal epithelial cells induces high grade prostate intraepithelial neoplasia. Prostate (2014) 0.84

Cross-talk between Wnt/β-catenin and Hippo signaling pathways: a brief review. BMB Rep (2014) 0.84

Screening with a novel cell-based assay for TAZ activators identifies a compound that enhances myogenesis in C2C12 cells and facilitates muscle repair in a muscle injury model. Mol Cell Biol (2014) 0.84

The Hippo pathway in intestinal regeneration and disease. Nat Rev Gastroenterol Hepatol (2016) 0.82

Wnt and FGF mediated epithelial-mesenchymal crosstalk during lung development. Dev Dyn (2014) 0.82

Wnt/β-catenin signaling regulated SATB1 promotes colorectal cancer tumorigenesis and progression. Oncogene (2015) 0.82

Ski regulates Hippo and TAZ signaling to suppress breast cancer progression. Sci Signal (2015) 0.81

Prognostic impact of TAZ and β-catenin expression in adenocarcinoma of the esophagogastric junction. Diagn Pathol (2014) 0.81

YAP enhances the pro-proliferative transcriptional activity of mutant p53 proteins. EMBO Rep (2015) 0.81

Nanotopographical Surfaces for Stem Cell Fate Control: Engineering Mechanobiology from the Bottom. Nano Today (2014) 0.81

Targeting pleiotropic signaling pathways to control adult cardiac stem cell fate and function. Front Physiol (2014) 0.81

Wnt activated β-catenin and YAP proteins enhance the expression of non-coding RNA component of RNase MRP in colon cancer cells. Oncotarget (2015) 0.81

Extracellular Matrix Stiffness Regulates Osteogenic Differentiation through MAPK Activation. PLoS One (2015) 0.80

CDK1 phosphorylation of TAZ in mitosis inhibits its oncogenic activity. Oncotarget (2015) 0.80

Histone acetylation-mediated regulation of the Hippo pathway. PLoS One (2013) 0.80

Verteporfin inhibits YAP function through up-regulating 14-3-3σ sequestering YAP in the cytoplasm. Am J Cancer Res (2015) 0.80

Maternal Wnt/STOP signaling promotes cell division during early Xenopus embryogenesis. Proc Natl Acad Sci U S A (2015) 0.80

Yap and Taz regulate retinal pigment epithelial cell fate. Development (2015) 0.80

The cellular prion protein PrPc is a partner of the Wnt pathway in intestinal epithelial cells. Mol Biol Cell (2015) 0.79

The hippo tumor suppressor network: from organ size control to stem cells and cancer. Cancer Res (2013) 0.79

ABL kinases promote breast cancer osteolytic metastasis by modulating tumor-bone interactions through TAZ and STAT5 signaling. Sci Signal (2016) 0.79

Point mutations in the tumor suppressor Smad4/DPC4 enhance its phosphorylation by GSK3 and reversibly inactivate TGF-β signaling. Mol Cell Oncol (2015) 0.79

The Hippo signaling pathway provides novel anti-cancer drug targets. Oncotarget (2016) 0.79

Overexpression of FZD7 promotes glioma cell proliferation by upregulating TAZ. Oncotarget (2016) 0.79

COP9 signalosome subunit 6 (CSN6) regulates E6AP/UBE3A in cervical cancer. Oncotarget (2015) 0.78

TAZ Protein Accumulation Is Negatively Regulated by YAP Abundance in Mammalian Cells. J Biol Chem (2015) 0.78

Tumorigenesis: WNT branches out. Nat Rev Cancer (2013) 0.78

Mieap suppresses murine intestinal tumor via its mitochondrial quality control. Sci Rep (2015) 0.78

Wnt signaling in triple-negative breast cancer. Oncogenesis (2017) 0.78

Wnt versus Hippo: A balanced act or dynamic duo? Genes Dis (2014) 0.77

Angiomotin stabilization by tankyrase inhibitors antagonizes constitutive TEAD-dependent transcription and proliferation of human tumor cells with Hippo pathway core component mutations. Oncotarget (2016) 0.77

Regulation of sensitivity of tumor cells to antitubulin drugs by Cdk1-TAZ signalling. Oncotarget (2015) 0.77

(-)-Epicatechin gallate (ECG) stimulates osteoblast differentiation via Runt-related transcription factor 2 (RUNX2) and transcriptional coactivator with PDZ-binding motif (TAZ)-mediated transcriptional activation. J Biol Chem (2014) 0.76

The hippo signaling pathway: implications for heart regeneration and disease. Clin Transl Med (2014) 0.76

YAP/TAZ initiate and maintain Schwann cell myelination. Elife (2017) 0.76

CSN6 positively regulates c-Jun in a MEKK1-dependent manner. Cell Cycle (2015) 0.76

Physiological mechanisms and therapeutic potential of bone mechanosensing. Rev Endocr Metab Disord (2015) 0.76

Glucocorticoid receptor signalling activates YAP in breast cancer. Nat Commun (2017) 0.76

Wnt target genes and where to find them. F1000Res (2017) 0.75

PRKCZ methylation is associated with sunlight exposure in a North American but not a Mediterranean population. Chronobiol Int (2014) 0.75

Wnt Signaling Inhibition Deprives Small Intestinal Stem Cells of Clonogenic Capacity. Genesis (2016) 0.75

Molecular Control of Atypical Protein Kinase C: Tipping the Balance between Self-Renewal and Differentiation. J Mol Biol (2016) 0.75

Disease implication of hyper-Hippo signalling. Open Biol (2016) 0.75

Role of the Wnt signaling molecules in the tooth. Jpn Dent Sci Rev (2016) 0.75

Customized chemotherapy in metastatic non-small cell lung cancer (NSCLC). Transl Lung Cancer Res (2013) 0.75

Hippo signaling interactions with Wnt/β-catenin and Notch signaling repress liver tumorigenesis. J Clin Invest (2016) 0.75

IQGAP1 Binds to Yes-associated Protein (YAP) and Modulates Its Transcriptional Activity. J Biol Chem (2016) 0.75

G-protein-coupled receptors mediate ω-3 PUFAs-inhibited colorectal cancer by activating the Hippo pathway. Oncotarget (2016) 0.75

Cadherins Associate with Distinct Stem Cell-Related Transcription Factors to Coordinate the Maintenance of Stemness in Triple-Negative Breast Cancer. Stem Cells Int (2017) 0.75

Mice with a heterozygous Lrp6 deletion have impaired fracture healing. Bone Res (2016) 0.75

The role of the extracellular biophysical cues in modulating Hippo-YAP pathway. BMB Rep (2016) 0.75

Application Of Small Molecules Favoring Naïve Pluripotency during Human Embryonic Stem Cell Derivation. Cell Reprogram (2015) 0.75

Hypoxia-inducible factor 2α (HIF-2α) promotes colon cancer growth by potentiating Yes-associated protein 1 (YAP1) activity. J Biol Chem (2017) 0.75

Tankyrase inhibitors suppress hepatocellular carcinoma cell growth via modulating the Hippo cascade. PLoS One (2017) 0.75

Cytoplasmic and Nuclear TAZ Exert Distinct Functions in Regulating Primed Pluripotency. Stem Cell Reports (2017) 0.75

Positive regulation of TAZ expression by EBV-LMP1 contributes to cell proliferation and epithelial-mesenchymal transition in nasopharyngeal carcinoma. Oncotarget (2016) 0.75

Hippo Pathway: An Emerging Regulator of Craniofacial and Dental Development. J Dent Res (2017) 0.75

Articles by these authors

Role of YAP/TAZ in mechanotransduction. Nature (2011) 11.56

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89

Mapping Wnt/beta-catenin signaling during mouse development and in colorectal tumors. Proc Natl Acad Sci U S A (2003) 7.60

Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest (2006) 6.61

Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med (2007) 6.55

A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell (2009) 6.03

MicroRNA control of signal transduction. Nat Rev Mol Cell Biol (2010) 5.74

The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell (2011) 5.06

Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol (2009) 4.89

A MicroRNA targeting dicer for metastasis control. Cell (2010) 4.81

Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet (2009) 4.35

Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood (2010) 4.17

FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination. Cell (2009) 4.11

Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol (2010) 4.09

The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med (2007) 4.04

Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med (2008) 3.98

Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity (2010) 3.88

Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet (2008) 3.69

Links between tumor suppressors: p53 is required for TGF-beta gene responses by cooperating with Smads. Cell (2003) 3.45

A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. Cell (2013) 3.17

Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J Neurosci (2004) 3.12

Transduction of mechanical and cytoskeletal cues by YAP and TAZ. Nat Rev Mol Cell Biol (2012) 3.07

IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood (2012) 3.02

Emilin1 links TGF-beta maturation to blood pressure homeostasis. Cell (2006) 2.84

Methods for interpreting lists of affected genes obtained in a DNA microarray experiment. BMC Proc (2009) 2.80

Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol (2011) 2.76

Wnt/beta-catenin signaling acts upstream of N-myc, BMP4, and FGF signaling to regulate proximal-distal patterning in the lung. Dev Biol (2005) 2.73

Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nat Med (2013) 2.67

Germ-layer specification and control of cell growth by Ectodermin, a Smad4 ubiquitin ligase. Cell (2005) 2.66

Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias. J Exp Med (2011) 2.59

Beta-catenin is required for endothelial-mesenchymal transformation during heart cushion development in the mouse. J Cell Biol (2004) 2.57

SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors. Nature (2012) 2.46

Novel definition files for human GeneChips based on GeneAnnot. BMC Bioinformatics (2007) 2.32

Wnt/beta-catenin signaling directs multiple stages of tooth morphogenesis. Dev Biol (2007) 2.26

Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood (2004) 2.19

Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood (2011) 2.18

Reciprocal requirements for EDA/EDAR/NF-kappaB and Wnt/beta-catenin signaling pathways in hair follicle induction. Dev Cell (2009) 2.17

Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation. Nat Med (2010) 2.10

MicroRNA control of Nodal signalling. Nature (2007) 2.09

Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood (2009) 2.08

A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood (2011) 2.03

Activation of beta-catenin signaling programs embryonic epidermis to hair follicle fate. Development (2008) 1.96

Argininosuccinate lyase deficiency: mutational spectrum in Italian patients and identification of a novel ASL pseudogene. Hum Mutat (2007) 1.91

Genetic loss of SH2B3 in acute lymphoblastic leukemia. Blood (2013) 1.87

WT1 mutations in T-ALL. Blood (2009) 1.75

Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia. Blood (2013) 1.73

Late recurrence of childhood T-cell acute lymphoblastic leukemia frequently represents a second leukemia rather than a relapse: first evidence for genetic predisposition. J Clin Oncol (2011) 1.71

Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell (2008) 1.70

BMP signaling controls muscle mass. Nat Genet (2013) 1.68

Unexpected structural and functional consequences of the R33Q homozygous mutation in cardiac calsequestrin: a complex arrhythmogenic cascade in a knock in mouse model. Circ Res (2008) 1.67

Integration of TGF-beta and Ras/MAPK signaling through p53 phosphorylation. Science (2007) 1.65

USP15 is a deubiquitylating enzyme for receptor-activated SMADs. Nat Cell Biol (2011) 1.61

The reconstruction of transcriptional networks reveals critical genes with implications for clinical outcome of multiple myeloma. Clin Cancer Res (2011) 1.61

Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol (2005) 1.58

Toward the identification of a tolerogenic signature in IDO-competent dendritic cells. Blood (2005) 1.56

Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood (2007) 1.56

The Wnt/beta-catenin pathway regulates Gli-mediated Myf5 expression during somitogenesis. Development (2006) 1.55

Proapoptotic effect of hepatitis C virus CORE protein in transiently transfected cells is enhanced by nuclear localization and is dependent on PKR activation. J Hepatol (2004) 1.52

Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene (2005) 1.51

A leukemia-enriched cDNA microarray platform identifies new transcripts with relevance to the biology of pediatric acute lymphoblastic leukemia. Haematologica (2005) 1.50

The effects of siRNA-mediated inhibition of E2A-PBX1 on EB-1 and Wnt16b expression in the 697 pre-B leukemia cell line. Haematologica (2006) 1.49

Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150. Blood (2011) 1.47

Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma. Stem Cells (2010) 1.40

Treatment reduction in highly selected standard-risk childhood acute lymphoblastic leukemia. The AIEOP ALL-9501 study. Haematologica (2005) 1.40

miR-34b targets cyclic AMP-responsive element binding protein in acute myeloid leukemia. Cancer Res (2009) 1.39

Beta-catenin controls differentiation of the retinal pigment epithelium in the mouse optic cup by regulating Mitf and Otx2 expression. Development (2009) 1.39

Oxygen tension controls the expansion of human CNS precursors and the generation of astrocytes and oligodendrocytes. Mol Cell Neurosci (2007) 1.38

MiR-34a targeting of Notch ligand delta-like 1 impairs CD15+/CD133+ tumor-propagating cells and supports neural differentiation in medulloblastoma. PLoS One (2011) 1.38

Negative control of Smad activity by ectodermin/Tif1gamma patterns the mammalian embryo. Development (2010) 1.35

Molecular pathways: YAP and TAZ take center stage in organ growth and tumorigenesis. Clin Cancer Res (2013) 1.34

Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. Br J Haematol (2008) 1.34

The side population of ovarian cancer cells is a primary target of IFN-alpha antitumor effects. Cancer Res (2008) 1.33

An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase. Br J Haematol (2008) 1.33